Arbutus Biopharma Corp expected to post a loss of 8 cents a share - Earnings Preview

Arbutus Biopharma

24/02/2025 12:32

* Arbutus Biopharma Corp  ABUS.OQ   ABUS.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2024
    * The Warminster Pennsylvania-based  company is expected to
report
a 27.1% decrease in revenue to $1.563 million from $2.15 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Arbutus Biopharma Corp
is for
a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $5.00​, above​ its last closing price of $3.42. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.09       -0.09      -0.09     Met     4.9
 Jun. 30 2024  -0.09       -0.10      -0.11     Missed  -13.6
 Mar. 31 2024  -0.11       -0.11      -0.10     Beat    9.1​
 Dec. 31 2023  -0.12       -0.12      -0.12     Met     -1.7
 ​​Sep.        -0.11       -0.11      -0.12     Missed  -5.4
 30 2023                                                
 Jun. 30 2023  -0.11       -0.11      -0.10     Beat    10.9​
 Mar. 31 2023  -0.14       -0.14      -0.10     Beat    26.5
 Dec. 31 2022  -0.13       -0.13      -0.14     Missed  -5.2
 This summary was machine generated February 24 at 12:32 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)